Biosimilars

COVID-19

Cataract Surgery

Cataract

Cataract Therapeutics

NeuroOp Guru

The Residency Report

Clinical Diagnosis

Cornea

Dry Eye Awareness

Dry Eye

Gene Therapy

Geographic Atrophy

IOL Advances

Imaging

Glaucoma Awareness

Glaucoma Insights

Therapeutic Glaucoma

Interventional Glaucoma

Ocular Allergy

Ocular Surface Disease

Optic Relief

Optometry

Pediatrics

Pharmacy

Indispensable

Practice Management

Presbyopia

Ptosis

Refractive Surgery

Refractive

Retina

Surgery

Technology

Therapeutics

Understanding Antibiotic Resistance

Workplace

News

All News

Contributors

Money Matters

Media

All Videos

Expert Interviews

Medical World News

Podcasts

Case Based Roundtable Series

Case of the Quarter

EyeView

Grand Rounds

Insights

Rapid Readout

Viewpoints

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Events

Publications

Digital Edition

Europe Ophthalmology Times

Modern Retina

Supplements and Featured Publications

Partners

Subscribe

Resources

Job Board

Articles

VivaVision Biotech reveals promising phase 2 trial results for VVN461, a new treatment for Non-Infectious Anterior Uveitis, showcasing safety and efficacy.

Positive topline results from phase 2 VVN461 trial for non-infectious anterior uveitis

New research reveals UBX1325's potential to significantly improve vision in diabetic macular edema patients, offering hope for innovative retinal therapies.

NEJM Evidence publishes results from Phase 2 BEHOLD study of UBX1325

Canadian investigators urged quick neuro-ophthalmologic referrals to limit the progress of life- and vision-threatening conditions.

Neuro-ophthalmologic evaluation crucial in differentiating benign from life-threatening diplopia

Sheryl brings a wealth of editorial experience to MJH Life Sciences’ Eye Care Network, having engaged with the readers and the greater ophthalmic community of 

for more than 20 years. As Group Editorial Director, Sheryl’s purview extends across the print and digital network of 

Ophthalmology Times, Ophthalmology Times Europe, Modern Retina 

 Prior to ophthalmology, Sheryl previously covered the fields of audiology and confectionery science/technology/manufacturing.

Sheryl is also passionate about the mission, vision and values of Ophthalmic World Leaders (OWL) and recently completed her term on its Board of Directors. She continues to volunteer as Editor-in-Chief of the organization’s 

Magazine. In 2013, she was honored with the group’s inaugural Rising Star Award.

In addition, she has served as a judge for 

 Health Care Heroes Awards program as well as the Jesse H. Neal National Business Journalism Awards.

From revised patient flow to smarter tech adoption, ophthalmologists share which changes from 2020 have become cornerstones of modern care—and how they’re preparing for the next big disruption

(Part 2) From ophthalmology’s lockdown to lasting change: The pandemic habits that stuck

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

About

Advertise

Privacy

Editorial Info

Editorial Board

Terms and Conditions

Contact Us

Do Not Sell My Personal Information

Ophthalmology Times - Ophthalmology news, articles, and events

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Glaucoma

View

Examining Real-World Evidence on Latest Therapies for Retinal Disease 

Perspectives on Latest Therapies: Faricimab and Aflibercept 8mg

Videos

Nikolas JS London, MD, FACS presents two cases, one with a 92-year-old woman with a long history of bilateral nAMD, and one with a 70-year-old man with IDDM.

Dr. London examines a case of longstanding bilateral neovascular age-related macular degeneration (AMD), focusing on the patient's clinical history, treatment challenges, and the potential impact of recent therapeutic advancements on management strategies.

A case of longstanding bilateral neovascular AMD

Dr. London discusses the implications of faricimab and aflibercept 8 mg in treating retinal diseases, highlighting their mechanisms, efficacy data, and potential to enhance patient outcomes in conditions like wet age-related macular degeneration.

Dr. London discusses a case of diabetic macular edema (DME) with persistent subretinal fluid, emphasizing the diagnostic considerations, treatment options, and the implications for patient outcomes in the context of evolving therapeutic approaches.

A case of DME with persistent subretinal fluid

Perspectives on Latest Therapies: Faricimab and Aflibercept 8mg

EP: 1.A case of longstanding bilateral neovascular AMD

EP: 2.Perspectives on Latest Therapies: Faricimab and Aflibercept 8mg

EP: 3.A case of DME with persistent subretinal fluid

Newsletter